In 2024, UAB "Swixx Biopharma" had revenue of 5.8 million EUR.
| year | 2024Latest | 2023 | 2022 |
|---|---|---|---|
Revenue | 5,8m € | 0 € -100.0% | 5,2m € |
Profit | - | - | - |
Assets | - | - | - |
Liabilities | - | - | - |
Equity | 1,2m € +30.2% | 905,8k € | - -100.0% |
Employees | - | - | - |
Overall rating | B+75/100 |
Financial health | 70/100 |
Credit history | 70/100 |
Legal history | 100/100 |
Business activity | 60/100 |
| Overall risk | Low |
No risk flags | |
Possible tax debts | |
No financial data available | |
Regular report filing | |
| Description | Registered |
|---|---|
| CEO |
UAB "Swixx Biopharma" is located at Vilnius, Bokšto g. 1-3, LT-01126, LT-LT-01126.
The shareholders of UAB "Swixx Biopharma" include 1 Lithuanian legal entities. View ownership details →
Yes, UAB "Swixx Biopharma" is registered as an active VAT payer with VAT number LT100009238214.
UAB "Swixx Biopharma" was founded on December 4, 2014. The company has been operating for 12 years.
| Indicator | Value | Rank | Comparison | |
|---|---|---|---|---|
Company age | 12 years | 19 - 23 | 60% | |
Net revenue | 5 753 408,00 € | 1 - 4 | 98% | |
Equity | 1 179 645,00 € | 1 - 3 | 100% | |
Registered capital | 2896,00 € | - | 90% |
Annual financial report for 2024.
Annual financial report for 2023.
Annual financial report for 2022.
Annual financial report for 2021.
Annual financial report for 2020.
Annual financial report for 2019.
Registered in the Lithuanian register of legal entities.